GHRP-2

GHRP-2, or Growth Hormone Releasing Peptide-2, is a synthetic hexapeptide with the sequence D-Ala-D-bNal-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of 817.97 Da. It belongs to the class of growth hormone secretagogues (GHS), compounds that stimulate pituitary growth hormone release through a mechanism distinct from endogenous growth hormone-releasing hormone (GHRH). Researchers have studied GHRP-2 extensively since the early 1990s as both a scientific probe of the somatotropic axis and a potential clinical tool for diagnosing and treating growth hormone deficiency.

The peptide is closely related to ghrelin, the endogenous gut-derived hormone discovered in 1999, because both bind to the same receptor — the growth hormone secretagogue receptor type 1a (GHS-R1a). In fact, GHRP-2 was instrumental in identifying this receptor before ghrelin itself was characterized. This historical role gives the compound particular scientific importance: it helped define an entirely new neuroendocrine signaling pathway.

Japan has approved pralmorelin as a diagnostic agent for growth hormone deficiency, where it is used in a standardized stimulation test to assess pituitary reserve. Outside Japan, the compound remains unapproved for any therapeutic indication, though it continues to be studied in research settings. A 2004 review in Drugs in R&D (PMID 15230633) documented the compound's pharmacology and clinical development history under several research designations including KP-102D and GPA-748.

Researchers are drawn to GHRP-2 for several reasons. It produces a strong, reproducible spike in growth hormone levels, making it useful for studying the pituitary's secretory capacity. It also stimulates appetite, as demonstrated in controlled human studies, which has prompted interest in its role in energy homeostasis research. Beyond its direct hormonal effects, GHRP-2 has attracted attention in body composition research, with scientists examining whether GH secretagogues offer metabolic benefits in conditions such as hypogonadism or age-related growth hormone decline. The compound's well-characterized pharmacokinetics and receptor pharmacology make it a reference compound against which newer secretagogues are often compared.

GHRP-2 exerts its effects primarily by binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor (GPCR) expressed in the anterior pituitary and the hypothalamus. Receptor activation triggers the Gq/11 signaling pathway, leading to phospholipase C (PLC) activation, inositol triphosphate (IP3) generation, and a subsequent rise in intracellular calcium concentration. This calcium surge stimulates exocytosis of growth hormone from somatotroph cells in the anterior pituitary.

Importantly, GHRP-2 does not act through the growth hormone-releasing hormone receptor (GHRHR). A 1998 study in Endocrine (PMID 9798733) confirmed that GHRP-2 fails to activate the GHRH receptor in GC cell models, distinguishing its signaling pathway from that of GHRH. Despite using a separate receptor, GHRP-2 and GHRH produce a synergistic increase in GH release when administered together, suggesting complementary mechanisms that converge on somatotroph secretory machinery.

At the hypothalamic level, GHRP-2 appears to amplify GH release by suppressing somatostatin (SRIF), the endogenous inhibitor of GH secretion, while also stimulating hypothalamic GHRH neurons. A 1996 study in the Journal of Pediatric Endocrinology and Metabolism (PMID 8887169) examined the interrelationships between GHRP-2, GHRH, and somatostatin during chronic administration, finding that the peptide's GH-stimulating effects were partially mediated through modulation of somatostatin tone.

Beyond the pituitary, GHS-R1a receptors are distributed in the hypothalamus, hippocampus, and peripheral tissues including the stomach. Activation of these receptors by GHRP-2 produces secondary effects including stimulation of appetite — an effect shared with the endogenous ligand ghrelin — as well as modest increases in adrenocorticotropic hormone (ACTH) and cortisol. A 1998 study in the Journal of Neuroendocrinology (PMID 9688350) demonstrated that GHRP-2 also elevates cyclic AMP (cAMP) levels in cultured pituitary tumor cells, pointing to partial activation of the adenylyl cyclase pathway in certain cell contexts, though this is considered a secondary mechanism. The net pharmacological profile is a potent, reproducible GH pulse that is dose-dependent and time-limited.

Research on GHRP-2 spans more than three decades and includes both animal models and human clinical studies, making it one of the better-characterized synthetic GH secretagogues.

A key early review published in the European Journal of Endocrinology in 1997 (PMID 9186261) catalogued the pharmacological properties of the growth hormone-releasing peptide family, situating GHRP-2 as one of the most potent members due to its strong binding affinity for GHS-R1a and its reliable induction of GH pulses in both animal and human subjects.

In humans, a 2005 study published in the Journal of Clinical Endocrinology and Metabolism (PMID 15699539) enrolled healthy male volunteers and demonstrated that intranasal administration of GHRP-2 increased food intake similarly to ghrelin, confirming a direct appetite-stimulating effect mediated through GHS-R1a. This was among the first controlled human studies to connect the GH secretagogue pathway to appetite regulation in a clinical setting.

For diagnostic applications, pralmorelin — the clinical name for GHRP-2 — has been used in Japan as part of a standardized growth hormone stimulation test. A 2014 review in Neurologia Medico-Chirurgica (Tokyo) (PMID 25070016) on adult growth hormone deficiency discussed diagnostic testing approaches, including secretagogue-based challenges, underscoring the compound's established utility in endocrine evaluation.

In body composition research, a 2020 review in Translational Andrology and Urology (PMID 32257855) discussed GH secretagogues including GHRP-2 in the context of managing body composition in hypogonadal men. The authors noted that while the GH axis and the androgen axis interact in regulating lean mass and fat distribution, clinical evidence for secretagogue-based interventions in this population remains preliminary, and no large randomized trials have established therapeutic endpoints.

Chronically administered GHRP-2 in human subjects was studied as early as 1996 (PMID 8887169), when researchers reported that repeated dosing maintained GH responsiveness without complete tachyphylaxis, though somatostatin dynamics were altered over time.

In anti-doping research, GHRP-2 has been a focus because athletes have used it as a performance-enhancing agent. A 2015 study in Drug Testing and Analysis (PMID 25809000) reported the detection of GHRP-2 and GHRP-6 in athlete urine samples, and a companion study (PMID 25869809) characterized urinary metabolites following nasal administration of multiple GH releasing peptides, providing analytical reference data for sports drug testing laboratories.

Animal data, particularly from rodent models, showed early that GHRP-2 increases GH pulse amplitude and frequency, promotes positive nitrogen balance, and may have cardioprotective properties, though the latter has not been confirmed in human trials. Human evidence is concentrated in short-duration pharmacokinetic and pharmacodynamic studies rather than long-term outcome trials.

Human studies have used GHRP-2 primarily via intravenous or intranasal routes in acute stimulation protocols. The 2005 JCEM study (PMID 15699539) administered GHRP-2 intranasally in doses designed to evaluate appetite and GH responses. Diagnostic protocols in Japan using pralmorelin as a stimulation test typically involve an intravenous dose of approximately 2 mcg/kg body weight. These doses are specific to short-duration diagnostic or pharmacodynamic experiments and do not constitute therapeutic dosing recommendations.

The safety profile of GHRP-2 in humans has been characterized primarily through short-term clinical studies rather than long-term controlled trials, which limits conclusions about chronic use.

In acute human studies, the most consistently reported effects are increased appetite, mild flushing, and transient elevations in cortisol and prolactin. The 2005 Journal of Clinical Endocrinology and Metabolism study (PMID 15699539) noted that GHRP-2 increased food intake in healthy men following intranasal administration, an effect attributed to GHS-R1a activation that is considered pharmacologically expected rather than adverse. Cortisol and ACTH elevations are reproducible findings across multiple studies and reflect the receptor's distribution in the hypothalamic-pituitary-adrenal axis.

No serious adverse events were reported in the published short-duration clinical studies reviewed here. The 1996 chronic administration study (PMID 8887169) did not document significant adverse effects during the study period, though the sample sizes in such studies were small.

Theoretical safety concerns associated with chronic GH elevation include fluid retention, joint discomfort, insulin resistance, and potential promotion of pre-existing neoplastic growth, all of which are known risks associated with exogenous growth hormone therapy. Whether GHRP-2's pulsatile, physiologically modulated GH release carries the same risk profile as continuous exogenous GH administration is not established.

Because GHRP-2 also raises cortisol and prolactin acutely, chronic use could hypothetically affect adrenal function and reproductive endocrinology, but no human data confirm these risks at the doses and durations studied.

Data on renal or hepatic toxicity are absent from the peer-reviewed literature reviewed here. Long-term safety studies in humans do not exist in the published record. The compound's use in athletic populations, as documented in anti-doping literature, occurred outside controlled research settings, and no systematic adverse event data from those populations are available. Any use outside approved diagnostic protocols carries uncharacterized risk.

GHRP-2 is approved in Japan as the diagnostic agent pralmorelin for growth hormone stimulation testing, but it holds no approved therapeutic indication in the United States or European Union. The bulk of active research involves its use as an analytical reference compound in anti-doping science, where laboratories continue to refine urinary detection methods for GHRP-2 and related peptides.

In the clinical endocrinology space, interest persists in GH secretagogues for adult growth hormone deficiency and age-related somatotropic decline, but GHRP-2 itself has not advanced into large Phase III trials for these indications. Newer oral secretagogues, particularly those with better bioavailability, have drawn investment away from GHRP-2 as a therapeutic candidate.

Research gaps include the absence of long-term human safety and efficacy data, lack of randomized controlled trials for any therapeutic endpoint, and limited understanding of GHRP-2's effects in specific patient populations such as older adults or those with metabolic disease. The compound continues to appear in body composition and sports medicine literature as a reference point for GH secretagogue pharmacology.